

ISSN: 0392-2936

EJGO

European Journal of Gynaecological Oncology

Edited by
A. ONNIS



I.R.O.G. CANADA Inc.

europaean journal of gynaecological oncology

an International Journal

Editors-in-Chief

A. Onnis **P. Bószé**
Montréal (Canada) *Budapest (Hungary)*

Associate Editor

M. Marchetti
Padua (Italy)

Assistant Editor

J. Wilson
San Diego - CA (USA)

Editorial Board

H. H. Allen, <i>London, Ontario (Canada)</i>	A. F. Fuller Jr., <i>Boston, MA (USA)</i>	J. Menczer, <i>Savyon (Israel)</i>
S. O. Anteby, <i>Jerusalem (Israel)</i>	H. E. Geisler, <i>Indianapolis, IN (USA)</i>	J. Monsonego, <i>Paris (France)</i>
P. Audet-Lapointe, <i>Montreal (Canada)</i>	A. Gerbault, <i>Villejuif (France)</i>	B. Patsner, <i>New Jersey, NJ (USA)</i>
L. Aurelian, <i>Baltimore, MD (USA)</i>	G. Gitsch, <i>Vienna (Austria)</i>	A. Pinotti, <i>São Paulo (Brasil)</i>
A. Ayhan, <i>Ankara (Turkey)</i>	A. Gorins, <i>Paris (France)</i>	S. M. Piver, <i>Buffalo, NY (USA)</i>
O. Balat, <i>Graziantep (Turkey)</i>	A.P.M. Heintz, <i>Utrecht (The Netherlands)</i>	S. Rakar, <i>Ljubljana (Slovenia)</i>
H. K. Barber, <i>New York, NY (USA)</i>	L. Ioannidou-Mouzaka, <i>Athens (Greece)</i>	K. S. Raju, <i>London, England (UK)</i>
A. Basta, <i>Krakow (Poland)</i>	C. A. F. Joslin, <i>Leeds, England (UK)</i>	L. Rob, <i>Prague (Czech Republic)</i>
U. Beller, <i>Jerusalem (Israel)</i>	A. I. Karseladze, <i>Moscow (Russia)</i>	J. H. Shepherd, <i>London, England (UK)</i>
H. C. Bender, <i>Dusseldorf (Germany)</i>	J. Klastersky, <i>Bruxelles (Belgium)</i>	P. Sismondi, <i>Turin (Italy)</i>
T. Charkviani, <i>Tbilisi (Georgia)</i>	V. Kozachenko, <i>Moscow (Russia)</i>	L. Ungár, <i>Budapest (Hungary)</i>
C. F. De Oliveira, <i>Coimbra (Portugal)</i>	B. Kralj, <i>Ljubljana (Slovenia)</i>	I. Vergote, <i>Leuven (Belgium)</i>
S. Dexeus Jr., <i>Barcelona (Spain)</i>	E. Kubista, <i>Vienna (Austria)</i>	J. B. Vermorken, <i>Amsterdam (The Netherlands)</i>
G. De Palo, <i>Milan (Italy)</i>	A. P. Kudelka, <i>Houston, TX (USA)</i>	P. Vírtej, <i>Bucharest (Romania)</i>
G. R. Di Paola, <i>Buenos Aires (Argentina)</i>	T. Maggino, <i>Padua (Italy)</i>	P.-H. Wang, <i>Taipei (Taiwan)</i>
F. Di Re, <i>Milan (Italy)</i>	J. Markowska, <i>Poznan (Poland)</i>	R. Winter, <i>Graz (Austria)</i>
P. Di Saia, <i>Orange, CA (USA)</i>	Leon F. A. G. Massuger, <i>Nijmegen (The Netherlands)</i>	Y. Yokoyama, <i>Hirosaki (Japan)</i>
S. K. Fotiou, <i>Athens (Greece)</i>		J. Zielinski, <i>Warsaw (Poland)</i>

Publisher Organization:

I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc
Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242-4893640 - Fax +514-4854513 - E-mail: canlux@qc.aira.com

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by **CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.**

European Journal of Gynaecological Oncology

General Information

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

AIMS AND SCOPE

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distinguished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the diffusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted 6 months before publication and will be published free of charge.

BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.

COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.

ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2H3, Tél. 514.4893242-4893640 - Fax 514.4854513 - E-mail: canlux@qc.aira.com

SUBSCRIPTION INFORMATION

The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

Subscriptions are entered with prepayment only. The annual subscription is \$390 US for Institutions, \$260 US for Individuals and \$120 US for Members of Society of Gynaecological Oncology all over the world. For air mail add \$30. Single copies prepaid cost \$95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner's) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. **Only US Funds are accepted.**

Claims for missing issues can be honoured up to six months. **Changes of address:** allow six weeks for all changes to become effective. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via Montona 4, Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and **any communication and requests should be addressed to** I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY

ISSN: 0392-2936

I.R.O.G. CANADA, Inc.

Editorial office: 4900 Côte St. Luc - Apt. 212 - Montréal, Québec H3W 2H3 (Canada) - Tél.: (514) 4893640-4893242 - Fax: (514) 4854513

E-mail: canlux@qc.aira.com

ALL RIGHTS RESERVED

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopies, recordings, nor any information storage and retrieval system without written permission from the copyright owner.

Printed in Italy

Cover figure: HUNDERTWASSER - work n. 78 *Hommes* from Exposition itinérante “L’Autriche présente Hundertwasser aux continents”, by kind concession of Gruener Janura AG Editions

European Journal of Gynaecological Oncology

Instructions to Authors

SUBMISSION OF MANUSCRIPTS

Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Storie 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the "Distinguished Expert Series" should be submitted to P. Bószé, Editor-in-Chief of this section, PO Box 46, 1031 Budapest, Hungary, Telephone (36-1) 275 2172, Fax (36-1) 275 2172, E-mail: bosze@mail.matav.hu.

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers' suggestions.

Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publication cannot be returned.

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author's experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and application thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS

The Journal follows the "Uniform requirements for manuscripts submitted to biomedical journals" published in the *New England Journal of Medicine* 1991, 324, 424-8 and in the *British Medical Journal* 1991, 302.

Three *manuscripts*, typed and double spaced should be submitted **with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0**. A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which they read and approved, and which has never been published or submitted for publication elsewhere. Name, address and phone/fax numbers of the *Corresponding Author*, responsible for revision and approval of the proofs, should be indicated. Full-length *articles* should not exceed 8 printed pages including tables and references.

After the *title page* (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: *Summary* (*purpose of investigation, methods, results, conclusion - about 150 words*), *Key words*, *Content* (a 20-word summary), *Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement* (if any), *References, Tables, Legends*.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

In general, **no more than six authors is considered appropriate**. Authors' names cannot be changed after submission.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author's name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. **If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).**

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first citation in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in *Index Medicus*. The titles of journals should be abbreviated according to the style used in *Index Medicus*.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors' surname and initials (if more than six names, give six followed by "et al."), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue, Pages.

Books: Authors' surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Pages.

Acknowledgments will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author by the publisher and should be checked and returned within 10 days. The corresponding author is responsible for detecting typesetting errors. After this deadline **the proofs will be considered as approved**. Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS

The Journal has no commercial advertisements. **Authors will be expected to contribute to the printing expenses, tables, clichés and postage**. For every published article a copy of the Journal will be provided free of charge. **Only payments in US dollars will be accepted.**

Reprints should be requested with the form enclosed with the acceptance letter.

No free reprints will be supplied. Authors should supply a complete address for reprint requests.

Individual subscribers are entitled to publish works, no longer than two printed pages with 25 reprints, free of charge (excluding tables, figures, illustrations, postage), and to have discounts on additional pages and on reprints over the 25 provided free of charge.

Contents - Volume XXII, n. 6, 2001

DISTINGUISHED EXPERT SERIES

Vulval intraepithelial neoplasia: current perspectives 393

R. W. Jones - *Auckland, NEW ZEALAND*

The heterogeneous clinical features of vulval intraepithelial neoplasia (VIN), its uncertain and variable natural history, difficulties in the management of certain cases and the frequency of recurrences provide a continuing challenge for gynaecologists. A more active approach to the diagnosis and management of VIN 3 may often prevent the development of vulval cancer. The increasing incidence of VIN and VIN-associated vulval cancer in young women provides very delicate problems in therapeutic management.

ORIGINAL ARTICLES

A ten-year remission maintained by 6272 mg (3920 mg/m²) cumulative dose of cisplatin-based chemotherapy for recurrent epithelial ovarian cancer 403

M. Steven Piver - *Buffalo, NY, USA*

A ten-year remission of recurrent epithelial ovarian cancer has been maintained by a total of 72 courses of cisplatin-based chemotherapy for a total cumulative dose of 6272 mg of cisplatin without major toxicity.

Treatment of metastatic invasive moles in two husband-side sisters-in-law. Case reports and review of literature 406

M. A. van Eijkeren, E. A. Sijmons, P. O. Witteveen, M. J. Verhaar, D. M. D. S. Sie-Go, A. P. M. Heintz - *Utrecht, THE NETHERLANDS*

The treatment of "high risk" persistent trophoblastic disease (PTD) consists of poly-chemotherapy. This policy probably will lead to overtreatment of some patients. Also, familiar molar pregnancies through the paternal line are unknown in the literature up til now. Treatment decisions should be made based on the concept of "high" or "low" risk PTD, but if histology becomes available, chemotherapy might be less aggressive in cases of invasive mole. If invasive mole could be familiar through the paternal line remains unclear with the current knowledge of genetics in trophoblastic disease.

Adjuvant radiotherapy in stage I-II epithelial ovarian cancer 409

I. Skirnisdóttir, B. Sorbe - *Örebro and Uppsala, SWEDEN*

Tumor recurrence rate in early (FIGO stage I-II) ovarian carcinoma is 30%. Adjuvant abdominopelvic radiotherapy was evaluated in a series of 113 patients.

Estrogen receptor expression in an endometrial stromal sarcoma after tamoxifen therapy 417

J. B. Liao, J. Y. Lin - *Washington, DC, USA*

Negative estrogen receptor expression in an endometrial stromal sarcoma exposed to tamoxifen suggests it may not be influenced by the partial estrogenic properties of tamoxifen.

Identifying local tumor variables for operable node-negative, margin-free patients with bulky cervical carcinoma of FIGO stage IB, IIA and IIB without adjuvant therapies 420

T. O. Loh, P. H. Wang, M. S. Yen, K. C. Chao, H. T. Ng, C. C. Yuan - *Taipei, TAIWAN*

Meticulous selection of patients with bulky cervical carcinoma to have surgical intervention only might also achieve similar survival rate with decreased morbidity.

Piver's radical hysterectomy (type III): Endo-Gia 30 stapler versus traditional forcipressure for resection of the cardinal ligament 423

P. Scollo, G. Scibilia, F. Nocera, R. Ruggeri, S. Caudullo - *Catania, ITALY*

The use of the Endo-Gia stapler for resection of cardinal ligaments in radical hysterectomy reduced time of operation, blood loss and overall costs and is easier than the traditional method with forcipressure.

Glutathione S-transferases P1-1 and A1-1 in ovarian cyst fluids 427

E. A. Boss, W. H. M. Peters, H. M. J. Roelofs, H. Boonstra, E. A. Steegers, L. F. A. G. Massuger - *Nijmegen, THE NETHERLANDS*

Glutathione S-transferases P1-1 and A1-1 were determined in 90 ovarian cyst fluid samples from histologically different tumors. Clinical relevance and relation to resistance to chemotherapy were investigated.

Immunohistochemical evaluation of a new epithelial antigen, Ber-EP4, in ovarian cancer: preliminary results 433

P. L. Cherchi, V. Marras, G. Capobianco, G. Ambrosini, M. Piga, G. M. Fadda, S. Dessole - *Sassari, ITALY*

The immunohistochemical expression of BerEP4 in ovarian cancer was related to the histotype and grading but not to clinical stage.

Drug resistance in epithelial ovarian cancer: P-glycoprotein and glutathione S-transferase. Can they play an important role in detecting response to platinum-based chemotherapy as a first-line therapy 436

T. Şimşek, G. Özbilim, H. Gülkesen, H. Kaya, F. Sargin, Ş. Karaveli - *Antalya, TURKEY*

Glutathione S-transferase and P-glycoprotein are important systems in drug resistance. The role of these systems in the treatment of epithelial ovarian cancer was investigated. Detecting glutathione S-transferase and P-glycoprotein levels in the epithelial ovarian cancer tissue is not predictive for response to platinum-based chemotherapy.

Preoperational diagnosis of a uterine lipoleiomyoma using ultrasound and computed tomography images: A case report	439
W. H. Su, P. H. Wang, S-P. Chang, M-C. Su - <i>Toa-Yuang, TAIWAN</i>	
A hyperechoic mass on ultrasound, and in addition with CT, confined to the uterus allows a possible preoperative diagnosis of uterine lipoleiomyomas.	
Transvaginal ultrasonography and hysterosonography to monitor endometrial effects in tamoxifen-treated patients	441
M. Valenzano, G. F. Bertelli, S. Costantini, A. Corticelli, L. Del Mastro, R. Paoletti, O. Garrone, R. Rissone - <i>Cuneo, ITALY</i>	
The aim of this work was to evaluate if hysterosonography can increase diagnostic accuracy during tamoxifen treatment and thus allow us to avoid further invasive investigations in patients with suggestive hysterosonographic features.	
Bilateral primary squamous cell carcinoma of the ovary: A case report of isolated metastasis to the lateral pelvic wall	445
Ö. Balat, A. Aydın, C. Camcı, İ. Kutlar, S. Büyükberber - <i>Gaziantep, TURKEY</i>	
A case of bilateral pure squamous cell carcinoma of the ovary to refractory radiotherapy and the multiple chemotherapeutic agents with a poor outcome is presented.	
Differential expression of α-smooth muscle actin molecule in a subset of bone marrow stromal cells, in b-cell chronic lymphocytic leukemia, autoimmune disorders and normal fetuses	447
N. Papadopoulos, C. Simopoulos, A. Kotini, M. Lambropoulou, I. Tolparidou, D. Tamiolakis - <i>Alexandroupolis, GREECE</i>	
α -smooth muscle actin is expressed in a distinct subpopulation of bone marrow stromal cells in normal fetuses, and pathological settings in adults.	
Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma	451
P. L. Cherchi, V. Marras, G. Capobianco, G. Ambrosini, M. D. Piga, G. M. Fadda, N. Rosas, S. Dessole - <i>Sassari, ITALY</i>	
The immunohistochemical over-expression of p53, c-erb-B2 and Ki-67/MIB-1 in endometrial carcinoma seemed to point out a more malignant tumour phenotype.	
Huge primary mucinous cystadenoma of the retroperitoneum mimicking a left ovarian tumor	454
O. Balat, A. Aydın, A. Şirikci, İ. Kutlar, F. Aksoy - <i>Gaziantep, TURKEY</i>	
A huge mucinous cyst adenoma of the retroperitoneum mimicking a left ovarian tumor that was totally removed without any complications is presented.	
Uterine serous papillary carcinoma: Clinical and immunopathological study of 9 cases	456
K. Sykiotis, A. Kondi-Pafiti, D. Giannaris, J. Kouvaris, A. Papayannopoulou, E. Salamalekis - <i>Athens, GREECE</i>	
Immunopathological characteristics of endometrial serous papillary adenocarcinoma were studied for a correct therapeutic approach.	
Women with a pelvic mass: Indicators of malignancy	459
G. C. Balbi, R. Musone, A. Menditto, F. Balbi, C. Corcioni, G. Calabria, C. Maciariello, C. Balbi - <i>Naples, ITALY</i>	
To discriminate the characteristics of pelvic masses it is useful to evaluate CA72-4 and Doppler ultrasonography associated with pelvic examination and transvaginal ultrasonography.	
Effect of prechemotherapy filgrastim on the bone marrow toxicity of topotecan	463
H. Ozan, F. Özkalemkas, Ü. Ozan, K. Özerkan, T. Bilgin, F. Küçükyıldız - <i>Bursa, TURKEY</i>	
Prechemotherapy filgrastim does not seem to deepen chemotherapy-related myelosuppression. On the contrary, it seems to have a beneficial effect that is worth being investigated further.	
Reproductive tract pathology in asymptomatic women treated with tamoxifen	466
K. Yüce, Z. S. Tuncer, C. Öncüoğlu, A. Ayhan, E. Baltalı, N. Güler - <i>Ankara, TURKEY</i>	
Since no significant genital pathology attributable to tamoxifen therapy could be detected, the follow-up for gynecologic pathologies in breast cancer patients receiving tamoxifen may be individualized.	
The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract	469
E. Topuz, Y. Eralp, A. Aydiner, P. Saip, F. Taş, E. Yavuz, Y. Salihoğlu - <i>Istanbul, TURKEY</i>	
Patients with malignant mixed mullerian tumors of the female genital tract treated at a single institution are presented and the role of chemotherapy in this subset of patients is further discussed.	
Contents index vol. XXII, 2001	473
Authors index vol. XXII, 2001	479

european journal of gynaecological oncology

Index

Volume XXII, n. 1, January-February 2001

EDITORIAL ESGO

- A. Gorins: *A report of the E.S.G.O. session during the Fifth European Meeting of the French Society of Gynecology "Recent data about endometrial carcinoma"* 5

DISTINGUISHED EXPERT SERIES

- D. V. Surbek, W. Holzgreve: *Fetal cells from cord blood as stem cell source: current status and possible implications in gynaecologic oncology* 6

ORIGINAL ARTICLES

- W. A. Tjalma, I. D. Cooremans, W. Jeuris, E. A. Van Marck, J. M. Monaghan: *Recurrent Paget's disease of the vulva in a myocutaneous flap: Case report and review of the literature* 13
- K. Holcomb, N. Gabbur, T. Tucker, R. P. Matthews, Y. C. Lee, O. Abulafia: *⁶⁰Cobalt vs. linear accelerator in the treatment of locally advanced cervix carcinoma: a comparison of survival and recurrence patterns* 16
- W. A. Tjalma, J. M. Monaghan, A. de Barros Lopes, R. Naik, A. Nordin: *Primary vaginal melanoma and long-term survivors* 20
- Y. Fukushi, S. Sato, Y. Yokoyama, K. Kudo, H. Maruyama, Y. Saito: *Detection of numerical aberration in chromosome 17 and c-erbB2 gene amplification in epithelial ovarian cancer using recently established dual color FISH* 23
- R. Naik, J. Nwabinielli, C. Mayne, A. Nordin, A. de Barros Lopes, J. M. Monaghan, P. Hilton: *Prevalence and management of (non-fistulous) urinary incontinence in women following radical hysterectomy for early stage cervical cancer* 26
- L. Savino, F. Borruto, C. Comparetto, G. B. Massi: *Radical vaginal hysterectomy with extraperitoneal pelvic lymphadenectomy in cervical cancer* 31
- A. Nordin, K. Abang Mohammed, R. Naik, A. de Barros Lopes, J. Monaghan: *Does long-term follow-up have a role for node negative squamous carcinoma of the vulva? The Gateshead experience* 36
- B. Zylberberg, D. Dormont, S. Jankiewicz, E. Darai, J. J. Bretel, C. Poncelet, J. L. Guillet, P. Madelenat: *Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer* 40
- Ö. Balat, C. L. Edwards, L. Delclos: *Advanced primary carcinoma of the Bartholin gland: Report of 18 patients* 46
- B. Prabha, J. Molykutty, A. Swapna, T. N. Rajalekshmi, V. P. Gangadharan: *Increased expression of Interleukin-1 beta is associated with persistence of the disease and invasion in complete hydatidiform moles (CHM)* 50
- P. H. Wang, C. C. Yuan, C. M. Juang, C. R. Lai, M. S. Yen, H. T. Chao, H. T. Ng: *Primary epithelial ovarian carcinoma in Taiwanese women* 57
- T. Fait, J. Zivny, P. Freitag, D. Kuzel: *Adenosarcoma of the uterine body in a 19-year-old woman - three year survival: Case report* 61

H. R. Cosiski Marana, J. M. de Andrade, A. do Carmo da Silva Matthes, L. A. Ribeiro Spina, H. H. Angotti Carrara, S. Bighetti: <i>Microinvasive carcinoma of the cervix. Analysis of prognostic factors</i>	64
G. A. Melilli, L. Nappi, C. Carriero, M. Lapresa, V. Loizzi, F. Caradonna, M. Quaranta, G. Putignano: <i>Malignant mixed mullerian tumor of the ovary: report of four cases</i>	67
E. Topuz, Y. Eralp, P. Saip, A. Aydiner, F. Taş, Y. Salihoğlu, S. Berkman, E. Bengisu: <i>The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage I C ovarian carcinoma</i>	70
V. Smyrniotis, D. Kehagias, A. Paphitis, N. Panagiopoulou, C. Syciotis, A. Antoniou: <i>Tailgut cysts: a rare cause of pelvic outlet obstruction</i>	74
I. K. El-Lamie: <i>Preliminary experience with Mainz type II pouch in gynecologic oncology patients</i>	77
O. Lehoczy, A. Bagaméri, J. Udvary, T. Pulay: <i>Side-effects of paclitaxel therapy in ovarian cancer patients</i>	81

Volume XXII, n. 2, March-April 2001

DISTINGUISHED EXPERT SERIES

C. H. Boardman, M. J. Webb: <i>Surgery in ovarian cancer</i>	89
--	----

EDITORIAL ESGO

J. Bonte: <i>Recent data about endometrial carcinoma: potential of anti-aromatase agents</i>	96
--	----

ESGO consensus document on cervical cancer screening

<i>Chair: J. Patnick, J. Monsonogo, C. de Wolf, A. Verbeek - ESGO Committee on Cervical and Breast Cancer Screening: J. Bonte (Chairman) - N. Agnantis, C. F. De Oliveira, S. Dexeus, T. Maggino, A. Onnis, J. Zielinski, Representatives for Screening of the European Countries</i>	99
---	----

ORIGINAL ARTICLES

R. V. M. Haughney, R. J. Slade, A. N. Brain: <i>An isolated abdominal wall metastasis of ovarian carcinoma ten years after primary surgery</i>	102
H. Ben-Hur, A. Ashkenazi, M. Huszar, P. Gurevich, I. Zusman: <i>Lymphoid elements and apoptosis-related proteins (Fas, Fas ligand, p53 and bcl-2) in lichen sclerosus and carcinoma of the vulva</i>	104
A. I. Karseladze: <i>On the site of origin of epithelial tumors of the ovary</i>	110
D. Colin, T. Lazure, M. Fabre, J. C. De Watteville, P. Bedossa: <i>Pleomorphic rhabdomyosarcoma of the uterine corpus: a case report</i>	116
Z. Holub, L. Kliment, J. Lukáč, J. Voráček: <i>Laparoscopically-assisted intraoperative lymphatic mapping in endometrial cancer: preliminary results</i>	118
R. Halperin, S. Zehavi, L. Habler, E. Hadas, I. Bukovsky, D. Schneider: <i>Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium</i>	122
C. Baykal, A. Al, E. Demirtaş, A. Ayhan: <i>Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: A randomised prospective double-blind clinical study</i>	127
N. Papadopoulos, D. Tamiolakis, M. Lambropoulou, G. Alexiadis, S. Deftereos, J. Manavis, A. Polychronidis, E. Sivridis: <i>Appraisal of imprint cytology in the diagnosis of mucinous carcinoma of the breast: a case report</i>	131
J. Markowska, N. Fischer, J. B. Warchol, Z. Fischer: <i>Detection of Chlamydia Trachomatis infection in women with CIN and invasive carcinoma. Controversial results of different methods</i>	134
W. Sawicki, B. Śpiewankiewicz, K. Cendrowski, J. Stelmachów: <i>Preoperative discrimination between malignant and benign adnexal masses with transvaginal ultrasonography and colour blood flow imaging</i>	137
A. Rodolakis, I. Papaspyrou, M. Sotiropoulou, S. Markaki, S. Michalas: <i>Primary squamous cell carcinoma of the endometrium. A report of 3 cases</i>	143

G. Porzio, C. Ficorella, G. Calvisi, I. Paris, E. Ricevuto, P. Marchetti: <i>Ductal breast carcinoma metastatic to the vulva: a case report</i>	147
N. Papadopoulos, D. Tamiolakis, M. Lambropoulou, G. Alexiadis, J. Manavis, P. Anastasiadis, E. Sivridis: <i>Primary diffuse large B-cell lymphoma of the breast: a case report</i>	149
T. Pekin, B. Yıldızhan, F. Eren, O. Pekin, R. Yıldızhan: <i>Adenocarcinoma, adenoacanthoma, and mixed adenosquamous carcinoma of the endometrium</i>	151
A. Altıntaş, M. A. Vardar: <i>Central nervous system involvement in gestational trophoblastic neoplasia</i>	154
C. Markopoulos, E. Kouskos, K. Kontzoglou, G. Gogas, V. Kyriakou, J. Gogas: <i>Breast cancer in ectopic breast tissue</i>	157
T. Pekin, Z. Kavak, B. Yıldızhan, H. Kaya: <i>Prognosis and treatment of primary adenocarcinoma and adenosquamous cell carcinoma of the uterine cervix</i>	160
Book Reviews	164

Volume XXII, n. 3, May-June 2001

Presidential address	169
--------------------------------	-----

EDITORIAL ESGO XII

A. Onnis: <i>Gynaecologic Oncology: looking back and moving ahead</i>	170
In memoriam	174

DISTINGUISHED EXPERT SERIES

M. Rodriguez, L. Dubeau: <i>Ovarian tumor development: insights from ovarian embryogenesis</i>	175
--	-----

COMMUNICATION SECTION

P. Bósze	184
--------------------	-----

ORIGINAL ARTICLES

An EORTC Gynecological Cancer Group Study: <i>Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced Fallopian tube carcinoma</i>	187
F. Amant, L. Dreyer, J. Makin, I. Vergote, B. G. Lindeque: <i>Uterine sarcomas in South African black women: a clinicopathologic study with ethnic considerations</i>	194
M. Matsushita, H. Kurata, H. Kase, M. Arakawa, Y. Aoki, K. Tanaka: <i>MR imaging underestimates stromal invasion in patients with adenocarcinoma of the uterine cervix</i>	201
M. F. D. Baay, W. A. A. Tjalma, J. Weyler, G. Goovaerts, P. Buytaert, E. A. E. Van Marck, F. Lardon, J. B. Vermorken: <i>Human papillomavirus infection in the female population of Antwerp, Belgium: prevalence in healthy women, women with premalignant lesions and cervical cancer</i>	204
A. Szánthó, I. Szabó, Zs. Csapó, J. Bálega, A. Demeter, Z. Papp: <i>Assessment of myometrial and cervical invasion of endometrial cancer by transvaginal sonography</i>	209
M. Krašević, H. Haller, Z. Iternička, I. Valstelić, N. Matejčić: <i>Adenoid cystic carcinoma of Bartholin's gland: A case report</i>	213
W. A. Tjalma, P. M. Buytaert, Z. N. Berneman: <i>Reduction of visible bone metastases by clodronate therapy in breast cancer</i>	215
M. Imai, T. Jobo, R. Sato, M. Kawaguchi, H. Kuramoto: <i>Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations</i>	217
S. Sinan Özalp, Ö. T. Yalçın, H. M. Tanir: <i>A hospital-based multicentric study results on gestational trophoblastic disease management status in a developing country</i>	221
C. Tropé, G. Kristensen, J. Kisic, J. Kaern: <i>Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer</i>	223

K. Yüce, C. Baykal, C. Genç, A. Al, A. Ayhan: <i>Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer</i>	228
V. Dousias, S. Chouliara, C. Zioga, G. Koliopoulos, E. D. Lolis, N. Dalkalitsis, E. Paraskevaïdis: <i>Replacement of the uterus by malignant mesothelioma of the peritoneum: A case report</i>	233
E. Diakomanolis, A. Elsheikh, Z. Voulgaris, A. Rodolakis, G. Vlachos, S. Michalas: <i>Cervical intraepithelial neoplasia in the young female. Diagnosis and management</i>	236
E. Kontogianni, E. Koukoura, E. Christopoulou: <i>Squamous cell carcinoma arising in mature cystic teratoma of the ovary: A case report</i>	238
H. Kaya, M. F. Evans, G. Ekicioglu, S. Tuzlali, S. Küllü, C. Foster: <i>Antimetastasis gene expression and numerical chromosomal abnormalities of chromosomes 1 & 17 in serous tumours of the ovary</i>	240
A. Elsheikh, S. Milingos, G. Kallipolitis, D. Loutradis, G. Vlachos, A. Liapi, S. Michalas: <i>Ovarian tumors in young females. A laparoscopic approach</i>	243

Volume XXII, n. 4, July-August 2001

DISTINGUISHED EXPERT SERIES

S. S. Witkin: <i>Heat shock protein expression and immunity: relevance to gynecologic oncology</i>	249
--	-----

ORIGINAL ARTICLES

F. L. Ampil, G. V. Burton, G. M. Mills, A. Jawahar, R. Pelsler, A. Nanda : <i>Cauda equina compression in breast cancer - incidence and treatment outcome</i>	257
I. Chattopadhyay, D. J. Cruickshank, M. Packer: <i>Non diethylstilbesterol induced vaginal adenosis - A case series and review of literature</i>	260
N. Umasaki, T. Tanaka, M. Miyama, S. Ogita, H. Ochi: <i>Usefulness of positron emission tomography for diagnosis of malignancy in a calcified lesion: A case report</i>	263
D. S. Chi, W. B. Jones, R. R. Barakat, K. N. O'Keefe, W. J. Hoskins, J. L. Lewis Jr.: <i>The benefit of a special elective gynecologic oncology program for obstetrics and gynecology residents</i>	266
F. L. Ampil, G. Caldito, J. Unger, P. Connor, R. Pelsler: <i>Can intermediate-risk node-negative patients with stage I corpus cancer do without posthysterectomy radiotherapy?</i>	269
N. Bhattacharya, K. Mukherjee, M. K. Chettri, T. Banerjee, S. Bhattacharya, A. Ghosh, M. Bhattacharya: <i>A unique experience with human pre-immune (12 weeks) and hypo-immune (16 weeks) fetal thymus transplant in a vascular subcutaneous axillary fold in patients with advanced cancer: A report of two cases</i>	273
C. G. Taylor, J. M. Sargent, A. W. Elgie, C. J. Williamson, G. M. Lewandowicz, O. Chappatte, J. G. Hill: <i>Chemosensitivity testing predicts survival in ovarian cancer</i>	278
W. H. Su, P. H. Wang, S-P. Chang: <i>Successful treatment of a persistent mole with myometrial invasion by direct injection of methotrexate</i>	283
F. Recchia, S. De Filippis, M. Rosselli, G. Saggio, G. Carta, S. Rea: <i>Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study</i>	287
R. Halperin, S. Zehavi, P. Dar, L. Habler, E. Hadas, I. Bukovsky, D. Schneider: <i>Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas</i>	292
H. Kobiashvili, L. Charkviani, T. Charkviani: <i>Organ preserving method in the management of atypical endometrial hyperplasia</i>	297
A. Stylianidou, M. Varras, C. Akrivis, A. Fylaktidou, S. Stefanaki, N. Antoniou: <i>Sclerosing stromal tumor of the ovary: A case report and review of the literature</i>	300
J. R. Kouvaris, V. E. Kouloulis, C. D. Loghis, E. J. Balafouta, A. C. Miliadou, L. J. Vlahos: <i>Minor prognostic factors in squamous cell vulvar carcinoma</i>	305

Volume XXII, n. 5, September-October 2001

Report ESGO 12th

- T. Maggino: *The development of Gynaecologic Oncology in the new millennium* 313

DISTINGUISHED EXPERT SERIES

- C. A. Strittmatter, M. Steven Piver: *The use of lymphadenectomy in clinical stage I endometrial adenocarcinoma at a large community hospital* 315

ORIGINAL ARTICLES

- P. Azevedo, C. F. Verschraegen, J. J. Kavanagh, A. P. Kudelka, R. S. Freedman, K. Lu, M. T. Deavers: *Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report* 319
- S. K. Parikh, A. Ravi, D. Yi-Shin Kuo, D. Nori: *Bullous pemphigoid masquerading as acute radiation dermatitis: Case report* 322
- K. O. Odunsi, S. Lele, S. Ghamande, P. Seago, D. L. Driscoll: *The impact of pre-therapy extraperitoneal surgical staging on the evaluation and treatment of patients with locally advanced cervical cancer* 325
- C. Lippert, H. Seeger, D. Wallwiener, A. O. Mueck: *The effect of medroxyprogesterone acetate and norethisterone on the estradiol stimulated proliferation in MCF-7 cells: comparison of continuous combined versus sequential combined estradiol/progestin treatment* 331
- T. Pejovic, A. Koul, D. Olsen, J. T. Chambers: *No BRCA1 germline mutation in a family with uterine papillary serous carcinoma: A case report* 336
- J. Fujimoto, H. Sakaguchi, I. Aoki, H. Toyoki, S. Khatun, T. Tamaya: *Inhibitory effect of ginsenoside-Rb2 on invasiveness of uterine endometrial cancer cells to the basement membrane* 339
- M. Kudela, R. Pilka: *Is there a real risk in patients with endometrial carcinoma undergoing diagnostic hysteroscopy (HSC)?* 342
- J. Manavis, G. Alexiadis, M. Lambropoulou, S. Deftereos, P. Argyropoulou, A. Giatromanolaki, E. Sivridis: *Extragenital retroperitoneal endodermal sinus tumor in an eight-month-old female infant* 345
- Z. Lian, J. Fujimoto, Y. Yokoyama, K. Niwa, T. Tamaya: *Herbal complex suppresses telomerase activity in chemo-endocrine resistant cancer cell lines* 347
- O. Balat, A. Aydın, İ. Kutlar, C. Camcı: *Ruptured granulosa cell tumor of the left ovary and mature cystic teratoma of the right ovary: A case report of unusual acute abdominal syndrome* 350
- A. Gadducci, A. Romanini: *Adjuvant chemotherapy in early stage uterine sarcomas: An open question* 352
- M. Yaldız, A. K. Uzunlar, N. Kılınc, A. Yalınkaya, M. Akkuş, S. Tunik: *Mucinous tumors of the ovary: Analysis of 38 cases* 358
- N. Papadopoulos, M. Lambropoulou, E. Sivridis, J. Manavis, P. Argyropoulou, G. Alexiadis, P. Askitis, K. Ioannakis, D. Tamiolakis: *Marginal-zone B-cell lymphoma, extranodal-malt-type: Report of three cases* 361
- T. Jobo, M. Kawaguchi, M. Imai, H. Kuramoto: *Treatment for complex atypical hyperplasia of the endometrium* 365
- D. Miliaras, S. Papaemmanouil, G. Blatzas: *Ovarian capillary hemangioma and stromal luteinization: a case study with hormonal receptor evaluation* 369
- T. Bese, S. Khalil Nomir: *The importance of serum insulin-like growth factor-I level determination in the follow-up of patients with epithelial ovarian cancer* 372
- A. Ayhan, I. Guney, B. Saygan-Karamursel, C. Taskiran: *Ovarian metastasis of primary biliary and gallbladder carcinomas* 377
- S. E. Akhan, G. Kılıc, Y. Salihoglu, E. Bengisu, S. Berkman: *Non genital metastatic cancers of the ovary: A clinical analysis* 379
- A. Kemal Uzunlar, A. Yalınkaya, M. Yaldiz, N. Kiliñç, T. Gül: *Survival and reproductive function after treatment of immature ovarian teratoma* 384
- O. Balat, M. Tercan, M. Bekerecioğlu, A. Aydın, M. Karakök, İ. Kutlar: *Adenoid cystic carcinoma of the vulva: Conservative surgery using a de-epithelized rhomboid flap* 387

Volume XXII, n. 6, November-December 2001

DISTINGUISHED EXPERT SERIES

- R. W. Jones: *Vulval intraepithelial neoplasia: current perspectives* 393

ORIGINAL ARTICLES

- M. Steven Piver: *A ten-year remission maintained by 6272 mg (3920 mg/m²) cumulative dose of cisplatin-based chemotherapy for recurrent epithelial ovarian cancer* 403
- M. A. van Eijkeren, E. A. Sijmons, P. O. Witteveen, M. J. Verhaar, D. M. D. S. Sie-Go, A. P. M. Heintz: *Treatment of metastatic invasive moles in two husband-side sisters-in-law. Case reports and review of literature* 406
- I. Skirnisdóttir, B. Sorbe: *Adjuvant radiotherapy in stage I-II epithelial ovarian cancer* 409
- J. B. Liao, J. Y. Lin: *Estrogen receptor expression in an endometrial stromal sarcoma after tamoxifen therapy* 417
- T. O. Loh, P. H. Wang, M. S. Yen, K. C. Chao, H. T. Ng, C. C. Yuan: *Identifying local tumor variables for operable node-negative, margin-free patients with bulky cervical carcinoma of FIGO stage IB, IIA and IIB without adjuvant therapies* 420
- P. Scollo, G. Scibilia, F. Nocera, R. Ruggeri, S. Caudullo: *Piver's radical hysterectomy (type III): Endo-Gia 30 stapler versus traditional forcipressure for resection of the cardinal ligament* 423
- E. A. Boss, W. H. M. Peters, H. M. J. Roelofs, H. Boonstra, E. A. Steegers, L. F. A. G. Massuger: *Glutathione S-transferases P1-1 and A1-1 in ovarian cyst fluids* 427
- P. L. Cherchi, V. Marras, G. Capobianco, G. Ambrosini, M. Piga, G. M. Fadda, S. Dessole: *Immunohistochemical evaluation of a new epithelial antigen, Ber-EP4, in ovarian cancer: preliminary results* 433
- T. Şimşek, G. Özbilim, H. Gülkesen, H. Kaya, F. Sargin, Ş. Karaveli: *Drug resistance in epithelial ovarian cancer: P-glycoprotein and glutathione S-transferase. Can they play an important role in detecting response to platinum-based chemotherapy as a first-line therapy* 436
- W. H. Su, P. H. Wang, S-P. Chang, M-C. Su: *Preoperational diagnosis of a uterine lipoleiomyoma using ultrasound and computed tomography images: A case report* 439
- M. Valenzano, G. F. Bertelli, S. Costantini, A. Corticelli, L. Del Mastro, R. Paoletti, O. Garrone, R. Rissone: *Transvaginal ultrasonography and hysterosonography to monitor endometrial effects in tamoxifen-treated patients* 441
- Ö. Balat, A. Aydın, C. Camcı, İ. Kutlar, S. Büyükberber: *Bilateral primary squamous cell carcinoma of the ovary: A case report of isolated metastasis to the lateral pelvic wall* 445
- N. Papadopoulos, C. Simopoulos, A. Kotini, M. Lambropoulou, I. Tolparidou, D. Tamiolakis: *Differential expression of α -smooth muscle actin molecule in a subset of bone marrow stromal cells, in b-cell chronic lymphocytic leukemia, autoimmune disorders and normal fetuses* 447
- P. L. Cherchi, V. Marras, G. Capobianco, G. Ambrosini, M. D. Piga, G. M. Fadda, N. Rosas, S. Dessole: *Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma* 451
- O. Balat, A. Aydın, A. Şirikci, İ. Kutlar, F. Aksoy: *Huge primary mucinous cystadenoma of the retroperitoneum mimicking a left ovarian tumor* 454
- K. Sykiotis, A. Kondi-Pafiti, D. Giannaris, J. Kouvaris, A. Papayannopoulou, E. Salamalekis: *Uterine serous papillary carcinoma Clinical and immunopathological study of 9 cases* 456
- G. C. Balbi, R. Musone, A. Menditto, F. Balbi, C. Corcioni, G. Calabria, C. Maciariello, C. Balbi: *Women with a pelvic mass: Indicators of malignancy* 459
- H. Ozan, F. Özkalemkas, Ü. Ozan, K. Özerkan, T. Bilgin, F. Küçükıldız: *Effect of prechemotherapy filgrastim on the bone marrow toxicity of topotecan* 463
- K. Yüce, Z. S. Tuncer, C. Öncüoğlu, A. Ayhan, E. Baltalı, N. Güler: *Reproductive tract pathology in asymptomatic women treated with tamoxifen* 466
- E. Topuz, Y. Eralp, A. Aydiner, P. Saip, F. Taş, E. Yavuz, Y. Salihoğlu: *The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract* 469
- Contents index vol. XXII, 2001 473
- Authors index vol. XXII, 2001 479

Index of Authors in alphabetical order

- Abang Mohammed K., 36
 Abulafia O., 16
 Agnantis N., 99
 Akhan S. E., 379
 Akkuş M., 358
 Akrivis C., 300
 Aksoy F., 454
 Al A., 127, 228
 Alexiadis G., 131, 149, 345, 361
 Altıntaş A., 154
 Amant F., 194
 Ambrosini G., 433, 451
 Ampil F. L., 257, 269
 Anastasiadis P., 149
 Antigoti Carrara H. H., 64
 Antoniou A., 74
 Antoniou N., 300
 Aoki I., 339
 Aoki Y., 201
 Arakawa M., 201
 Argyropoulou P., 345, 361
 Ashkenazi A., 104
 Askitis P., 361
 Aydın A., 350, 387, 445, 454
 Aydiner A., 70, 469
 Ayhan A., 127, 228, 377, 466
 Azevedo P., 319
- Baay M. F. D., 204
 Bagaméri A., 81
 Balafouta E. J., 305
 Balat Ö., 46, 350, 387, 445, 454
 Balbi C., 459
 Balbi F., 459
 Balbi G. C., 459
 Bálega J., 209
 Baltalı E., 466
 Banerjee T., 273
 Barakat R. R., 266
 Baykal C., 127, 228
 Bedossa P., 116
 Bekerecioğlu M., 387
 Bengisu E., 70, 379
 Ben-Hur H., 104
 Berkman S., 70, 379
 Berneman Z. N., 215
 Bertelli G. F., 441
 Bese T., 372
 Bhattacharya M., 273
 Bhattacharya N., 273
 Bhattacharya S., 273
 Bighetti S., 64
 Bilgin T., 463
 Blatzas G., 369
 Bósze P., 184
 Boardman C. H., 89
 Bonte J., 96
 Boonstra H., 427
 Borruto F., 31
 Boss E. A., 427
 Brain A. N., 102
 Bretel J. J., 40
 Bukovsky I., 122, 292
- Burton G. V., 257
 Buytaert P. M., 204, 215
 Büyükberber S., 445
- Calabria G., 459
 Caldito G., 269
 Calvisi G., 147
 Camcı C., 350, 445
 Capobianco G., 433, 451
 Caradonna F., 67
 Carriero C., 67
 Carta G., 287
 Caudullo S., 423
 Cendrowski K., 137
 Chambers J. T., 336
 Chang S-P., 283, 439
 Chao H. T., 57
 Chao K. C., 420
 Chappatte O., 278
 Charkviani L., 297
 Charkviani T., 297
 Chattopadhyay I., 260
 Cherchi P. L., 433, 451
 Chettri M. K., 273
 Chi D. S., 266
 Chouliara S., 233
 Christopoulou E., 238
 Colin D., 116
 Comparetto C., 31
 Connor P., 269
 Cooremans I. D., 13
 Corcioni C., 459
 Corticelli A., 441
 Cosiski Marana H. R., 64
 Costantini S., 441
 Cruickshank D. J., 260
 Csapó Zs., 209
- Dalkalitsis N., 233
 Dar P., 292
 Darai E., 40
 de Andrade J. M., 64
 de Barros Lopes A., 20, 26, 36
 De Filippis S., 287
 De Oliveira C. F., 99
 De Watteville J. C., 116
 de Wolf C., 99
 Deavers M. T., 319
 Deftereos S., 131, 345
 Del Mastro L., 441
 Delclos L., 46
 Demeter A., 209
 Demirtaş E., 127
 Dessole S., 433, 451
 Dexeus S., 99
 Diakomanolis E., 236
 do Carmo da Silva Matthes A., 64
 Dormont D., 40
 Dousias V., 233
 Dreyer L., 194
 Driscoll D. L., 325
 Dubeau L., 175
- Edwards C. L., 46
 Ekicioglu G., 240
 Elgie A. W., 278
- El-Lamie I. K., 77
 Elsheikh A., 236, 243
 Eralp Y., 70, 469
 Eren F., 151
 Evans M. F., 240
- Fabre M., 116
 Fadda G. M., 433, 451
 Fait T., 61
 Ficorella C., 147
 Fischer N., 134
 Fischer Z., 134
 Foster C., 240
 Freedman R. S., 319
 Freitag P., 61
 Fujimoto J., 339, 347
 Fukushi Y., 23
 Fylaktidou A., 300
- Gabbur N., 16
 Gadducci A., 352
 Gangadharan V. P., 50
 Garrone O., 441
 Genç C., 228
 Ghamande S., 325
 Ghosh A., 273
 Giannaris D., 456
 Giatromanolaki A., 345
 Gogas G., 157
 Gogas J., 157
 Goovaerts G., 204
 Gorins A., 5
 Guillet J. L., 40
 Gül T., 384
 Güler N., 466
 Gülkesen H., 436
 Guney I., 377
 Gurevich P., 104
- Habler L., 122, 292
 Hadas E., 122, 292
 Haller H., 213
 Halperin R., 122, 292
 Haughney R. V. M., 102
 Heintz A. P. M., 406
 Hill J. G., 278
 Hilton P., 26
 Holcomb K., 16
 Holub Z., 118
 Holzgreve W., 6
 Hoskins W. J., 266
 Huszar M., 104
- Imai M., 217, 365
 Ioannakis K., 361
 Iternička Z., 213
- Janklewicz S., 40
 Jawahar A., 257
 Jeuris W., 13
 Jobo T., 217, 365
 Jones R. W., 393
 Jones W. B., 266
 Juang C. M., 57
- Kaern J., 223
 Kallipolitis G., 243
- Karakök M., 387
 Karaveli Ş., 436
 Karseladze A. I., 110
 Kase H., 201
 Kavak Z., 160
 Kavanagh J. J., 319
 Kawaguchi M., 217, 365
 Kaya H., 160, 240, 436
 Kehagias D., 74
 Kemal Uzunlar A., 384
 Khalil Nomir S., 372
 Khatun S., 339
 Kılıc G., 379
 Kılınç N., 358, 384
 Kisic J., 223
 Kliment L., 118
 Kobiashvili H., 297
 Koliopoulos G., 233
 Kondi-Pafiti A., 456
 Kontogianni E., 238
 Kontzoglu K., 157
 Kotini A., 447
 Koukoura E., 238
 Koul A., 336
 Kouloulis V. E., 305
 Kouskos E., 157
 Kouvaris J. R., 305, 456
 Krašević M., 213
 Kristensen G., 223
 Küçük yıldız F., 463
 Kudela M., 342
 Kudelka A. P., 319
 Kudo K., 23
 Küllü S., 240
 Kuramoto H., 217, 365
 Kurata H., 201
 Kutlar İ., 350, 387, 445, 454
 Kuzel D., 61
 Kyriakou V., 157
- Lai C. R., 57
 Lambropoulou M., 131, 149, 345, 361, 447
 Lapresa M., 67
 Lardon F., 204
 Lazure T., 116
 Lee Y. C., 16
 Lehoczky O., 81
 Lele S., 325
 Lewandowicz G. M., 278
 Lewis J. L. Jr., 266
 Lian Z., 347
 Liao J. B., 417
 Liapi A., 243
 Lin J. Y., 417
 Lindeque B. G., 194
 Lippert C., 331
 Loghis C. D., 305
 Loh T. O., 420
 Loizzi V., 67
 Lolis E. D., 233
 Loutradis D., 243
 Lu K., 319
 Lukáč J., 118
- Maciariello C., 459
 Madelenat P., 40
 Maggino T., 99, 313

- Makin J., 194
 Manavis J., 131, 149, 345, 361
 Marchetti P., 147
 Markaki S., 143
 Markopoulos C., 157
 Markowska J., 134
 Marras V., 433, 451
 Maruyama H., 23
 Massi G. B., 31
 Massuger L. F. A. G., 427
 Matejčić N., 213
 Matsushita M., 201
 Matthews R. P., 16
 Mayne C., 26
 Melilli G. A., 67
 Menditto A., 459
 Michalas S., 143, 236, 243
 Miliadou A. C., 305
 Miliaras D., 369
 Milingos S., 243
 Mills G. M., 257
 Miyama M., 263
 Molykutty J., 50
 Monaghan J. M., 13, 20, 26, 36
 Monsonego J., 99
 Mueck A. O., 331
 Mukherjee K., 273
 Musone R., 459

 Naik R., 20, 26, 36
 Nanda A., 257
 Nappi L., 67
 Ng H. T., 57, 420
 Niwa K., 347
 Nocera F., 423
 Nordin A., 20, 26, 36
 Nori D., 322
 Nwabinelli J., 26

 O'Keefe K. N., 266
 Ochi H., 263
 Odunsi K. O., 325
 Ogita S., 263
 Olsen D., 336
 Öncüoğlu C., 466
 Onnis A., 99, 170
 Ozan H., 463
 Ozan Ü., 463
 Özbilim G., 436
 Özerkan K., 463
 Özkalemkas F., 463

 Packer M., 260
 Panagiotopoulos N., 74
 Paoletti R., 441
 Papadopoulos N., 131, 149, 361, 447
 Papaemmanouil S., 369
 Papaspyrou I., 143
 Papayannopoulou A., 456
 Paphitis A., 74
 Papp Z., 209
 Paraskevaidis E., 233
 Parikh S. K., 322
 Paris I., 147
 Patnick J., 99
 Pejovic T., 336
 Pekin O., 151
 Pekin T., 151, 160
 Pelser R., 257, 269
 Peters W. H. M., 427
 Piga M. D., 433, 451
 Pilka R., 342
 Polychronidis A., 131
 Poncelet C., 40
 Porzio G., 147
 Prabha B., 50
 Pulay T., 81
 Putignano G., 67

 Quaranta M., 67

 Rajalekshmi T. N., 50
 Ravi A., 322
 Rea S., 287
 Recchia F., 287
 Ribeiro Spina L. A., 64
 Ricevuto E., 147
 Rissone R., 441
 Rodolakis A., 143, 236
 Rodriguez M., 175
 Roelofs H. M. J., 427
 Romanini A., 352
 Rosas N., 451
 Rosselli M., 287
 Ruggeri R., 423

 Saggio G., 287
 Saip P., 70, 469
 Saito Y., 23
 Sakaguchi H., 339
 Salamalekis E., 456
 Salihoglu Y., 70, 469, 379
 Sargent J. M., 278
 Sargin F., 436
 Sato R., 217

 Sato S., 23
 Savino L., 31
 Sawicki W., 137
 Saygan-Karamursel B., 377
 Schneider D., 122, 292
 Scibilia G., 423
 Scollo P., 423
 Seago P., 325
 Seeger H., 331
 Sie-Go D. M. D. S., 406
 Sijmons E. A., 406
 Simopoulos C., 447
 Şimşek T., 436
 Sinan Özalp S., 221
 Şirikci A., 454
 Sivridis E., 131, 149, 345, 361
 Skirnisdóttir I., 409
 Slade R. J., 102
 Smyrniotis V., 74
 Sorbe B., 409
 Sotiropoulou M., 143
 Śpiewankiewicz B., 137
 Steegers E. A., 427
 Stefanaki S., 300
 Stelmachów J., 137
 Steven Piver M., 315, 403
 Strittmatter C. A., 315
 Stylianidou A., 300
 Su M-C., 439
 Su W. H., 283, 439
 Surbek D. V., 6
 Swapna A., 50
 Syciotis C., 74
 Sykiotis K., 456
 Szabó I., 209
 Szánthó A., 209

 Tamaya T., 339, 347
 Tamiolakis D., 131, 149, 361, 447
 Tanaka K., 201
 Tanaka T., 263
 Tanir H. M., 221
 Taş F., 70, 469
 Taskiran C., 377
 Taylor C. G., 278
 Tercan M., 387
 Tjalma W. A. A., 13, 20, 204, 215
 Tolparidou I., 447
 Topuz E., 70, 469
 Toyoki H., 339
 Tropé C., 223

 Tucker T., 16
 Tuncer Z. S., 466
 Tunik S., 358
 Tuzlali S., 240

 Udvary J., 81
 Umesaki N., 263
 Unger J., 269
 Uzunlar A. K., 358

 Valenzano M., 441
 Valstelić I., 213
 van Eijkeren M. A., 406
 Van Marck E. A. E., 13, 204
 Vardar M. A., 154
 Varras M., 300
 Verbeek A., 99
 Vergote I., 194
 Verhaar M. J., 406
 Vermorken J. B., 204
 Verschraegen C. F., 319
 Vlachos G., 236, 243
 Vlahos L. J., 305
 Voráček J., 118
 Voulgaris Z., 236

 Wallwiener D., 331
 Wang P. H., 57, 283, 420, 439
 Warchol J. B., 134
 Webb M. J., 89
 Weyler J., 204
 Williamson C. J., 278
 Witkin S. S., 249
 Witteveen P. O., 406

 Yalçin Ö. T., 221
 Yıldız M., 358, 384
 Yalınkaya A., 358, 384
 Yavuz E., 469
 Yen M. S., 57, 420
 Yıldızhan B., 151, 160
 Yıldızhan R., 151
 Yi-Shin Kuo D., 322
 Yokoyama Y., 23, 347
 Yuan C. C., 57, 420
 Yüce K., 228, 466

 Zehavi S., 122, 292
 Zielinski J., 99
 Zioga C., 233
 Zivny J., 61
 Zusman I., 104
 Zylberberg B., 40